entertainment -WSS

entertainment

author：focus 2025-09-30 19:25:14 - browse：8982

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

WSS

Aspartame and sugar

Treatments for cramps don't cut it. Why aren't there better options?

Illinois Supreme Court finds assault weapons ban constitutional

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

The Biogen Aduhelm mess could happen again

Adopting new red light myopia treatments may be short

knowledge

entertainment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

At least 13 dead in Texas as scorching temps continue

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Hollywood unions extend contract negotiations for actors

Biden administration begins canceling student loan debt for 804,000 borrowers

Medical leaders decry Supreme Court decision on affirmative action

Novo Nordisk touts Wegovy study, but still struggling with supply

Alkermes shareholders re

Schizophrenia gene found to be linked to cells' energy dysfunction

entertainment

Texas Medical Board asked to define abortion emergency exception

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Surge in Apellis stock fueled by confidence in safety of its eye drug

What’s missing from the debate over nursing home staff minimums

Surge in Apellis stock fueled by confidence in safety of its eye drug

Mark Cuban is blaming the wrong people for high drug costs

entertainment

hotspot

hotspot

entertainment